卵巢癌患者临床试验入组的影响因素
该回顾性研究分析了2009年10月至2013年4月诊断为II-IV期上皮性卵巢癌并接受一线化疗的患者,其中67%入组了临床试验。入组患者显著更年轻(中位61岁 vs 68岁,p=0.002),但分期、种族、体能状态和距离均无显著差异;入组患者3年生存率更高(70.7% vs 51.7%,p=0.031)。
要点
- 在常规提供临床试验的机构中,33%的初治上皮性卵巢癌患者未参与试验。
- 年龄增长与未参与试验相关,入组患者中位年龄61岁 vs 未入组68岁。
- 入组试验患者3年生存率70.7% vs 未入组51.7%(p=0.031)。
核心结论
- 在常规向所有合格患者提供临床试验的机构中,33%的初治晚期上皮性卵巢癌患者未参与试验。
- 年龄增长与未参与试验相关,需克服可改变的障碍以使试验入组更好反映真实上皮性卵巢癌人群特征。
研究设计与样本
- 回顾性综述,纳入2009年10月至2013年4月诊断为II-IV期上皮性卵巢癌并接受一线化疗的患者。
- 共144例符合研究标准,记录入组状态、人口学特征、肿瘤特征和治疗细节,使用SAS 9.3分析。
主要发现
- 144例患者中67%入组了临床试验,入组患者显著更年轻(中位61岁 vs 68岁,p=0.002)。
- 分期(p=0.30)、种族(p=0.75)和体能状态(p=0.38)在入组与未入组患者间相似。
- 距离未影响入组,两组中近半数患者距治疗中心超过50英里(39.0% vs 47.8%,p=0.36)。
- 化疗给药方式基于参与情况显著不同(所有p<0.05),残留病灶状态(p=1.00)和接受的化疗方案数(p=0.59)相似。
- 入组试验患者3年生存率更高(70.7% vs 51.7%,p=0.031);中位无进展生存期差异接近显著(20.2 vs 9.2个月,p=0.091)。
关键数值与推荐
- 入组患者中位年龄61岁 vs 未入组68岁(p=0.002)。
- 两组距治疗中心超过50英里的比例分别为39.0%和47.8%(p=0.36)。
- 入组试验患者3年生存率70.7% vs 未入组51.7%(p=0.031)。
- 中位无进展生存期20.2个月 vs 9.2个月(p=0.091)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize patients who did not enroll on a clinical trial and identify barriers that may limit enrollment among patients with advanced epithelial ovarian cancer (EOC) presenting for first-line chemotherapy. METHODS: We conducted a retrospective review of patients diagnosed with stage II-IV EOC from 10/2009-4/2013, a time period during which multiple trials were available to all EOC patients, including optimally debulked, suboptimally debulked, or undergoing neoadjuvant chemotherapy. Enrollment status, demographics, tumor characteristics, and treatment details were recorded. SAS version 9.3 was used for all analyses. RESULTS: 144 patients met study criteria; 67% were enrolled on a trial. Enrolled patients were significantly younger (median 61 vs 68years, p=0.002). Stage (p=0.30), race (p=0.75), and performance status (p=0.38) were similar between enrolled and non-enrolled patients. Distance did not impact enrollment, as nearly half of patients in both groups lived >50miles from the treatment center (39.0% vs 47.8%, p=0.36). Mode of chemotherapy administration significantly differed based on participation (all p<0.05). Despite similar residual disease status (p=1.00) and number of chemotherapy regimens received (p=0.59), patients treated on trial had a higher 3-year survival rate (70.7% vs 51.7%, p=0.031). The difference in median progression-free survival approached significance (20.2 vs 9.2months, p=0.091). CONCLUSION: In an institution where the culture is to offer clinical trials to all eligible patients, 33% of front-line EOC patients did not participate. Increasing age was associated with non-participation. Modifiable barriers must be overcome so that trial enrollment can better reflect true EOC demographics.
引用
- Greenwade MM, Moore KN, Gillen JM, et al. Factors influencing clinical trial enrollment among ovarian cancer patients. Gynecol Oncol. 2017. PMID: 28689668. doi:10.1016/j.ygyno.2017.06.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。